<DOC>
	<DOCNO>NCT00192634</DOCNO>
	<brief_summary>Combination antiretroviral therapy treatment HIV high pill burden . Two dual-tablets , abacavir-lamivudine tenofovir-emtricitabine , license United States available Australia December 2005 . Data available suggest potency tablet similar control replication HIV virus , directly compare regard clinically significant toxicity . We therefore aim compare overall safety efficacy two dual-tablets 2 year period HIV infect adult . We hypothesise two dual-NRTI treatment similar efficacy safety .</brief_summary>
	<brief_title>A Randomised , Open-label Trial Assess Safety Efficacy Switching Tenofovir-emtricitabine Abacavir-lamivudine : The STEAL Study</brief_title>
	<detailed_description>The aim study compare overall safety efficacy two dual-NRTI , daily , tablet 2 year period HIV infect adult . The study randomise , multi-centre , 2 year study two dual NRTI , daily tablet subject HIV , currently take two individual NRTIs part therapy . 350 subject randomise 1:1 ratio either : 1. tenofovir ( TDF ) 300mg + emtricitabine ( FTC ) 200mg OR 2. abacavir ( ABC ) 600mg + lamivudine ( 3TC ) 300mg . Subjects cease current individual NRTI treatment , commence randomise dual NRTI tablet , continue current NNRTI PI therapy . Subjects stratify type NRTI currently take ( ABC , TDF ) ; whether currently take protease inhibitor ( yes ) ; site randomise . A study plan enclose Subjects closely monitor ( 1 month every 3 month week 96 ) safety evaluate incidence severity adverse effects/abnormal laboratory parameter . Study investigation enclose . It optional whether subject also provide plasma , serum cell ( PBMCs ) storage . These sample available analysis sub-studies agree IVRN expression interest network .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>document HIV infection age least 18 year stable ( ≥ 12 week ) ART include least two NRTIs , currently well tolerate , plan change component ART regimen baseline HIV RNA &lt; 50 copies/mL plasma precede 12 week GFR ≥ 70 mL/min/1.73m2 ( estimate abbreviate MDRD equation23 estimate GFR = 186 x ( [ SCR/88.4 ] 1.154 ) x age0.203 x ( 0.742 female ) x ( 1.210 AfricanAmerican ) provision write , informed consent HLAB*5701 positive screening OR evidence previous ABC hypersensitivity OR clinical failure participant take abacavir least 30 day current therapy comprise triple NRTI therapy alone current use ABC/3TC FDC ( Kivexa ) TDF/FTC FDC ( Truvada ) history nontraumatic osteoporotic fracture prior hypersensitivity intolerance ABC , 3TC , TDF FTC prior clinical failure regimen contain ABC TDF prior use TDF control previously active hepatitis B ( HBsAg+ HBV DNA+ ) patient likely resistant 3TC/FTC current therapy include unboosted atazanavir concurrent use aminoglycosides , IV amphotericin B , cidofovir , cisplatin , foscarnet , IV pentamidine , probenecid , adefovir immunomodulatory agent clinical evidence cirrhosis ( e.g . smooth liver , feature portal hypertension ) creatinine clearance &lt; 50 mL/min ( estimate CockcroftGault equation ) 18,19 Male : ( 140 age year ) x ( wt kg ) = CLCr ( mL/min ) 0.814 x ( serum creatinine µmol/L ) Female : ( 140 age year ) x ( wt kg ) x 0.85 = CLCr ( mL/min ) 0.814 x ( serum creatinine µmol/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>HIV</keyword>
	<keyword>Antiretroviral therapy</keyword>
	<keyword>nucleoside analogue reverse transcriptase</keyword>
	<keyword>fix dose combination</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>